Akari Therapeutics PLC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Akari Therapeutics reports a substantial increase in net loss for Q1 2026, driven by significant non-cash impairment charges on goodwill and intangible assets, while cash reserves dwindle.
NASDAQ
Akari Therapeutics reported substantial losses and a going concern warning for Q3 2025, despite a strategic shift to its ADC platform and recent capital raises.
NASDAQ
Akari Therapeutics reported a significantly reduced net loss in the first half of 2025, driven by strategic pipeline prioritization, but continues to face substantial doubt about its ability to continue as a going concern without further financing.
NASDAQ
Akari Therapeutics reports a net loss of $3.7 million for Q1 2025, shifting focus to its antibody-drug conjugate (ADC) platform and pipeline.
NASDAQ
Akari Therapeutics reports a net loss of $16 million for the nine months ended September 30, 2024, and announces the completion of its merger with Peak Bio, along with a strategic pipeline prioritization.
NASDAQ
10-Q: Akari Therapeutics Reports Q2 2024 Results, Focuses on Strategic Merger and Pipeline Prioritization
Akari Therapeutics reported its second quarter 2024 results, highlighting a strategic shift towards a merger with Peak Bio and a focus on its PAS-nomacopan program for geographic atrophy.
NASDAQ
Akari Therapeutics reported a net loss of $5.6 million for the first quarter of 2024 and announced a strategic shift to focus on its PAS-nomacopan program and Peak Bio's ADC platform, suspending its HSCT-TMA program.